II. Indications
- See Cachexia in Cancer
- See Geriatric Failure to Thrive
- See Nausea in Terminally Ill Patients
- Synthetic Tetrahydrocannabinol (THC)
- Anorexia in Chronic Renal Failure
- Chemotherapy induced Nausea or Vomiting
- Cachexia in AIDS
- Purified Cannabidiol (CBD, Epidiolex)
- Lennox–Gastaut Syndrome (rare Seizure Disorder)
- Dravet Syndrome (rare Seizure Disorder)
- Combined THC and CBD
- Chronic Neuropathic pain
- Oral Mucosal spray and oral agents may offer small pain relief (NNT 10)
- May also demonstrate small improvement in sleep quality and physical functioning
- High THC to CBD ratios offer greatest relief, but also are with the greatest adverse effects
- Busse (2021) BMJ 374: n2040 [PubMed]
- Seehusen (2022) Am Fam Physician 106(2): 202-4 [PubMed]
- Cancer Related Pain
- Reduces mean pain intensity scores, but does not reduce overall pain scores, Insomnia, or Opioid use
- Hauser (2023) Cochrane Database Syst Rev (6): CD014915 [PubMed]
- Chronic Neuropathic pain
III. Mechanism: Two product types derived from Marijuana and Hemp
- Although THC and CBD are the best studied extracts, Cannabis contains more than 60 active substances
- Synthetic Tetrahydrocannabinol (THC)
- THC is the most psychoactive substance in Cannabis
- Will generate a positive Urine Drug Screen
- Purified Cannabidiol (CBD)
- Does not cause the "high" seen with THC (does not cause Intoxication or euphoria)
- However non-regulated CBD products frequently contain intoxicating THC levels
- Typically will not generate a positive Urine Drug Screen (but may if trace THC in product)
IV. Dosing: Cannabidiol (CBD)
- Preparations
- Cannabidiol (Epidiolex) oral solution
- FDA approved in U.S. as of 2018, with a cost of $32,000/year
- DEA Schedule 5
- OTC products (various forms)
- Legal status depends on U.S. State
- Not regulated or studied for efficacy and safety
- Contamination with intoxicating levels of THC are not uncommon
- Contamination with Pesticides and Heavy Metals has also been reported
- Cannabidiol (Epidiolex) oral solution
- Indications: Used to treat rare forms of childhood Epilepsy (age over 2 years)
- Dravet Syndrome
- Lennox-Gastaut Syndrome
- Tuberous Sclerosis
- Dosing
- Dosed 2.5 mg/kg orally twice daily
- Start at 1.25 mg/kg orally twice daily (maintenance 2.5 mg bid) in moderate hepatic dysfunction
- Start at 0.5 mg/kg orally twice daily (maintenance 1 mg bid) in severe hepatic dysfunction
- May increase in weekly increments of 2.5 mg/kg orally twice daily
- Maximum: 20 mg/kg/day divided twice daily (10 mg/kg orally twice daily)
- Decrease maximum dose to 5 mg/kg twice daily in moderate hepatic dysfunction
- Decrease maximum dose to 2 mg/kg twice daily in severe hepatic dysfunction
- Dosed 2.5 mg/kg orally twice daily
- Monitoring: Risk of Hepatocellular Injury (esp. in combination with Valproate, Clobazam)
- Obtain AST, ALT and Total Bilirubin at baseline, 1 month, 3 months and 6 months and then periodically
V. Dosing: Synthetic Tetrahydrocannabinol (THC)
- Nabilone (Cesamet)
- THC analogue used to treat intractable Nausea, Vomiting (e.g. Chemotherapy)
- DEA Schedule 2
- Dosing
- Start 1 mg orally twice daily
- May increase to 2 mg orally twice daily as needed
- Maximum: 6 mg/day in divided doses
- Dronabinol (Marinol, Syndros)
- THC formulation Indicated for intractable Nausea, Vomiting (e.g. Chemotherapy, AIDS-related Anorexia)
- DEA Schedule 3 (misuse is less likely due to formulation)
- Chemotherapy-Induced Nausea or Vomiting (based on BSA in all ages)
- Dose 5 mg/m2 orally 1 to 3 hours before Chemotherapy
- May repeat 5 mg/m2 dose every 2 to 4 hours as needed up to 4 to 6 doses per day
- Maximum: 15 mg/m2
- Anorexia in AIDS
- Start: 2.5 mg orally (or SL, PR) twice daily
- May increase to 5 to 10 mg orally twice daily
- Maximum: 20 mg/day
VI. Drug Interactions: Cannabidiol (CBD)
- Cannabidiol inhibits CYP2C19, CYP2C8, CYP2C9
- Increases levels of Citalopram, Phenytoin, Amitriptyline, Valproic Acid, Warfarin
- Cannabidiol levels may be lowered
- Strong CYP3A4 Inducers lower CBD levels (e.g. St. John's Wort, Carbamazepine, Phenytoin, Rifampin)
- Strong CYP3A4 inhibitors raise CBD levels (e.g. Clarithromycin)
VII. Protocol: Chronic Neuropathic Pain
- Start with Cannabidiol (CBD) spray, tablet or sublingual oil drops
- Initial: 5 mg orally twice daily
- Next: Increase total daily dose by 10 mg up to every 2 to 3 days to a maximum of 40 mg/day
- Add Tetrahydrocannabinol (THC)
- Initial: 1 to 2.5 mg/day
- Next: Increase by 1 to 2.5 mg/day every 2 to 7 days to a maximum of 40 mg/day
- References
- (2022) Am Fam Physician 106(2): 208-9
- Busse (2021) BMJ 374:n2040 +PMID: 34497062 [PubMed]
VIII. Adverse Effects: CBD
- Drowsiness or sedation (esp. in combination with other CNS Depressants, Alcohol, Sedative Hypnotics)
- Diarrhea
- Liver Function Test abnormalities
IX. Safety
- Avoid THC and CBD in pregnancy, Lactation and those taking multiple medications
- Check CBD product for a certificate of analysis that reports CBD levels, THC levels and contaminants
X. Resources
- Simplified Guideline for prescribing Medical Cannabinoids in Primary Care
- Dronabinol (DailyMed)
- Nabilone (DailyMed)
XI. References
- (2019) Presc Lett 26(6)
- (2018) Presc Lett 25(4)
- (2018) Presc Lett 25(9):51
- (2019) Med Lett Drugs Ther 61(1585): 179-82 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
dronabinol (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
DRONABINOL 10 MG CAPSULE | Generic | $3.22 each |
DRONABINOL 2.5 MG CAPSULE | Generic | $1.20 each |
DRONABINOL 5 MG CAPSULE | Generic | $2.45 each |